Literature DB >> 27862691

Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency.

G N Pike1,2, A M Cumming3, J Thachil1, C R M Hay1,4, J Burthem1,2, P H B Bolton-Maggs4,5.   

Abstract

INTRODUCTION: Previous guidelines recommend that FXI:C levels should be used to monitor FXI replacement in factor XI (FXI) deficiency. However, FXI:C levels do not correlate with bleeding tendency in this disorder and may not be the optimal test by which to monitor and determine further treatment in the postoperative period. AIM: To assess whether the thrombin generation assay (TGA) and rotational thromboelastometry can be used to monitor FXI replacement peri-operatively in FXI deficiency and to determine if changes in FXI:C levels correlate with changes in thrombin generation and clot formation parameters following treatment with solvent-detergent fresh frozen plasma (SD-FFP).
METHODS: The TGA and rotational thromboelastometry were used to measure thrombin generation and clot formation in 11 adults with FXI deficiency who were treated with either SD-FFP (n = 8) or FXI concentrate (n = 3) as prophylaxis peri-operatively. Blood samples were taken pre- and 30 min post-treatment.
RESULTS: Global haemostasis assays can be used to measure the effect of FXI replacement with SD-FFP or FXI concentrate in FXI deficiency. Both treatment types improved thrombin generation and clot formation. However, the remaining response to treatment at 24 h post SD-FFP was variable and changes in FXI:C levels were not predictive of changes in thrombin generation/thromboelastometry parameters after treatment with SD-FFP.
CONCLUSION: Global haemostasis assays may provide a more reliable means of monitoring SD-FFP treatment with the potential to prevent individuals receiving unnecessary treatment, however, their clinical use in decision making needs to be tested in a larger prospective study.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  bleeding disorder; blood coagulation; factor XI; factor XI deficiency; thrombin generation; thromboelastometry

Mesh:

Year:  2016        PMID: 27862691     DOI: 10.1111/hae.13112

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis.

Authors:  Alejandro Pallares Robles; Vincent Ten Cate; Andreas Schulz; Jürgen H Prochaska; Steffen Rapp; Thomas Koeck; Marina Panova-Noeva; Stefan Heitmeier; Stephan Schwers; Kirsten Leineweber; Hans-Jürgen Seyfarth; Christian F Opitz; Henri Spronk; Christine Espinola-Klein; Karl J Lackner; Thomas Münzel; Miguel A Andrade-Navarro; Stavros V Konstantinides; Hugo Ten Cate; Philipp S Wild
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

2.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22

3.  Successful hemostatic management of major surgery for cervical spondylotic myelopathy in a patient with severe factor XI deficiency.

Authors:  Yoshiyuki Ogawa; Kunio Yanagisawa; Yuri Uchiyama; Naoki Akashi; Tokue Mieda; Haku Iizuka; Madoka Inoue; Reiko Shizuka; Masami Murakami; Naomichi Matsumoto; Hiroshi Handa
Journal:  Int J Hematol       Date:  2018-04-30       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.